A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates

Science Translational Medicine

Volumn 4, Issue 154, 2012, Pages

  Cook, Douglas J ^a   Teves, Lucy ^a   Tymianski, Michael ^a,b  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPROTECTIVE AGENT; TAT NR2B9C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOEMBOLIC STROKE; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEASIBILITY STUDY; MACACA; MALE; NEUROPROTECTION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; TRANSLATIONAL RESEARCH; VALIDATION PROCESS;

ANIMALS; DISEASE MODELS, ANIMAL; MAGNETIC RESONANCE IMAGING; NEUROPROTECTIVE AGENTS; PEPTIDES; PRIMATES; STROKE;

EID: 84867222320     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003824     Document Type: Article

References (32)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333, 1581-1587 (1995).
2. W. Hacke, M. Kaste, E. Bluhmki, M. Brozman, A. Daválos, D. Guidetti, V. Larrue, K. R. Lees, Z. Medeghri, T. Machnig, D. Schneider, R. von Kummer, N. Wahlgren, D. Toni; ECASS Investigators, Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359, 1317-1329 (2008).
3. The bitterest pill. Nature 444, 532-533 (2006).
4. V. E. O'Collins, M. R. Macleod, G. A. Donnan, L. L. Horky, B. H. van der Worp, D. W. Howells, 1,026 experimental treatments in acute stroke. Ann. Neurol. 59, 467-477 (2006).
5. M. L. Sacchetti, Is it time to definitely abandon neuroprotection in acute ischemic stroke? Stroke 39, 1659-1660 (2008).
6. M. Philip, M. Benatar, M. Fisher, S. I. Savitz, Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke 40, 577-581 (2009).
7. H. B. van der Worp, P. de Haan, E. Morrema, C. J. Kalkman, Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia. J. Neurol. 252, 1108-1114 (2005).
8. M. Fisher, New approaches to neuroprotective drug development. Stroke 42, S24-S27 (2011).
9. S. I. Savitz, M. Fisher, Future of neuroprotection for acute stroke: In the aftermath of the SAINT trials. Ann. Neurol. 61, 396-402 (2007).
10. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30, 2752-2758 (1999).
11. M. Fisher, G. Feuerstein, D. W. Howells, P. D. Hurn, T. A. Kent, S. I. Savitz, E. H. Lo; STAIR Group, Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40, 2244-2250 (2009).
12. M. Aarts, Y. Liu, L. Liu, S. Besshoh, M. Arundine, J. W. Gurd, Y. T. Wang, M. W. Salter, M. Tymianski, Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 298, 846-850 (2002).
13. R. Sattler, Z. Xiong, W. Y. Lu, M. Hafner, J. F. MacDonald, M. Tymianski, Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 284, 1845-1848 (1999).
14. F. X. Soriano, M. A. Martel, S. Papadia, A. Vaslin, P. Baxter, C. Rickman, J. Forder, M. Tymianski, R. Duncan, M. Aarts, P. Clarke, D. J. Wyllie, G. E. Hardingham, Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J. Neurosci. 28, 10696-10710 (2008).
15. H. S. Sun, T. A. Doucette, Y. Liu, Y. Fang, L. Teves, M. Aarts, C. L. Ryan, P. B. Bernard, A. Lau, J. P. Forder, M. W. Salter, Y. T. Wang, R. A. Tasker, M. Tymianski, Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. Stroke 39, 2544-2553 (2008).
16. B. T. Bråtane, H. Cui, D. J. Cook, J. Bouley, M. Tymianski, M. Fisher, Neuroprotection by freezing ischemic penumbra evolution without cerebral blood flow augmentation with a postsynaptic density-95 protein inhibitor. Stroke 42, 3265-3270 (2011).
17. D. J. Cook, L. Teves, M. Tymianski, Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature 483, 213-217 (2012).
18. G. Courtine, M. B. Bunge, J. W. Fawcett, R. G. Grossman, J. H. Kaas, R. Lemon, I. Maier, J. Martin, R. J. Nudo, A. Ramon-Cueto, E. M. Rouiller, L. Schnell, T. Wannier, M. E. Schwab, V. R. Edgerton, Can experiments in nonhuman primates expedite the translation of treatments for spinal cord injury in humans? Nat. Med. 13, 561-566 (2007).
19. D. Enard, F. Depaulis, H. Roest Crollius, Human and non-human primate genomes share hotspots of positive selection. PLoS Genet. 6, e1000840 (2010).
20. M. D. M. Hill, R. H. Martin, D. Mikulis, J. H. Wong, F. L. Silver, K. G. terBrugge, G. Milot, W. M. Clarke, R. L. MacDonald, M. E. Kelly, M. Boulton, I. Fleetwood, C. MacDougall, T. Gunnarsson, M. Chow, C. Lum, R. Dodd, J. Poublanc, T. Krings, A. M. Demchuk, M. Goyal, R. Anderson, J. Bishop, D. Garman, M. Tymianski, Safety and efficacy of NA-1 for neuroprotection in iatrogenic stroke after endovascular aneurysm repair: A randomized controlled trial. Lancet Neurol. 8 October 2012 (10.1016/S1474-4422(12)70225-9).
21. M. Cronqvist, R. Wirestam, B. Ramgren, L. Brandt, O. Nilsson, H. Säveland, S. Holtås, E. M. Larsson, Diffusion and perfusion MRI in patients with ruptured and unruptured intracranial aneurysms treated by endovascular coiling: Complications, procedural results, MR findings and clinical outcome. Neuroradiology 47, 855-873 (2005).
22. M. Fisher, The ischemic penumbra: Identification, evolution and treatment concepts. Cerebrovasc. Dis. 17 (Suppl. 1), 1-6 (2004).
23. J. A. Zivin, M. Fisher, U. DeGirolami, C. C. Hemenway, J. A. Stashak, Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 230, 1289-1292 (1985).
24. K. O. Lövblad, A. E. Baird, G. Schlaug, A. Benfield, B. Siewert, B. Voetsch, A. Connor, C. Burzynski, R. R. Edelman, S. Warach, Ischemic lesion volumes in acute stroke by diffusion-weighted magnetic resonance imaging correlate with clinical outcome. Ann. Neurol. 42, 164-170 (1997).
25. B. Roitberg, N. Khan, E. Tuccar, K. Kompoliti, Y. Chu, N. Alperin, J. H. Kordower, M. E. Emborg, Chronic ischemic stroke model in cynomolgus monkeys: Behavioral, neuroimaging and anatomical study. Neurol. Res. 25, 68-78 (2003).
26. P. Lyden, T. Brott, B. Tilley, K. M. Welch, E. J. Mascha, S. Levine, E. C. Haley, J. Grotta, J. Marler, Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 25, 2220-2226 (1994).
27. G. W. Albers, Diffusion-weighted MRI for evaluation of acute stroke. Neurology 51, S47-S49 (1998).
28. D. Russell, Cerebral microemboli and cognitive impairment. J. Neurol. Sci. 203-204, 211-214 (2002).
29. S. Schnaudigel, K. Gröschel, S. M. Pilgram, A. Kastrup, New brain lesions after carotid stenting versus carotid endarterectomy: A systematic review of the literature. Stroke 39, 1911-1919 (2008).
30. M. Cronqvist, R. Wirestam, B. Ramgren, L. Brandt, B. Romner, O. Nilsson, H. Säveland, S. Holtås, E. M. Larsson, Endovascular treatment of intracerebral arteriovenous malformations: Procedural safety, complications, and results evaluated by MR imaging, including diffusion and perfusion imaging. AJNR Am. J. Neuroradiol. 27, 162-176 (2006).
31. J. Mocco, D. A. Wilson, R. J. Komotar, J. Zurica, W. J. Mack, H. J. Halazun, R. Hatami, R. R. Sciacca, E. S. Connolly Jr., E. J. Heyer, Predictors of neurocognitive decline after carotid endarterectomy. Neurosurgery 58, 844-850 (2006).
32. P. B. Gorelick, A. Scuteri, S. E. Black, C. Decarli, S. M. Greenberg, C. Iadecola, L. J. Launer, S. Laurent, O. L. Lopez, D. Nyenhuis, R. C. Petersen, J. A. Schneider, C. Tzourio, D. K. Arnett, D. A. Bennett, H. C. Chui, R. T. Higashida, R. Lindquist, P. M. Nilsson, G. C. Roman, F. W. Sellke, S. Seshadri, American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Surgery and Anesthesia, Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42, 2672-2713 (2011).